Humanigen Inc

Humanigen — Investor Presentation (August 2018)

19 slides from Humanigen's investor presentation, Aug 21, 2018

  1. Slide 1: Enhancing T-Cell Therapies in Oncology

    Enhancing T - Cell Therapies in Oncology OTCQB: HGEN www.humanigen.com 1

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements This presentation contains forward - looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements reflect management’s current knowledge, assumptions, judgment and expectations regar

  3. Slide 3: Executive Summary (1 of 2)

    Executive Summary (1 of 2) CAR - T, one of the most exciting fields in biotech, is now a reality with 2 FDA - approved therapies available; Neurotoxicity (NT) and Cytokine Release Syndrome (CRS) adverse effects are significant impediments to CAR - T uptake and utility Evidence indicates that GM - CS

  4. Slide 4: Executive Summary (2 of 2)

    Executive Summary CAR - T market expanding rapidly with movement into earlier lines of hematologic cancers, solid tumors and combination therapy; significant investment in space Lenzilumab alongside other portfolio assets may offer CAR - T platform Additional potential pipeline value: Lenzilumab pha

  5. Slide 5: Experienced, Execution-Focused Leadership and Board

    Experienced , Execution - Focused Leadership and Board; Extensive CAR - T and Immuno - Oncology Expertise Cameron Durrant, MD, MBA CEO o Pharma and serial biotech exec o Pharmacia/Pfizer, J+J in the US; Merck, GSK in Europe o Biotech Exec Chairman, Chairman, CEO, CFO Greg Jester, CPA CFO o Decades o

  6. Slide 6: Recent Approvals Poised for Significant Growth

    CAR - T Recent Approvals Poised for Significant Growth 5 - 1 - 18 KYMRIAH FDA approval for adult B - NHL 10 - 19 - 17 YESCARTA FDA approval for adult B - NHL CARTOX Guidelines for CAR - T Toxicities Published 2017 2018 8 - 30 - 17 KYMRIAH FDA approval for pediatric and young adult B - ALL 6 Signific

  7. Slide 7: Example: Kite/Gilead Commitment to Expansion in Hem/Onc

    Example: Kite/Gilead Commitment to CAR - T Expansion in Hem/ Onc 7 Source: Gilead Q2 2018 Earnings Call Deck Slide

  8. Slide 8: Big Commercial, Partnering Opportunity to Enhance T Cell Therapy

    Big Commercial, Partnering Opportunity to Enhance T Cell Therapy 8

  9. Slide 9: NT and CRS Key Impediments to Uptake and Utility

    NT and CRS Key Impediments to Uptake and Utility of CAR - T Up to 87% with NT and 94% with CRS* One third/one half of patients have grade ≥3 NT, potential ICU admission Several deaths * Package insert for KYMRIAH, YESCARTA “ Anything that we could use to try to lessen the side effects of CAR - T wou

  10. Slide 10: Potential Role of GM-CSF as 'Master Switch' in Toxicities

    Potential Role of GM - CSF as ‘Master Switch’ in CAR - T Toxicities o GM - CSF generated from CAR - T cells, which come into contact with myeloid cells immediately upon infusion, stimulate other cytokines, trigger further trafficking and damage, leading to NT and/or CRS o In CAR - T clinical trials,

  11. Slide 11: Lenzilumab: First-in-Class, Anti-GM-CSF Monoclonal Antibody

    Lenzilumab : First - in - Class, Anti - GM - CSF Monoclonal Antibody Lenzilumab o Binds to and neutralizes circulating GM - CSF Lenzilumab shown to be generally safe and well tolerated in >100 patients in one Phase I and two Phase II studies Key patent through 2029, submitted extensions in CAR - T t

  12. Slide 12: Lenzilumab Proven Pre-Clinical Safety and Toxicity Package

    Lenzilumab Proven Pre - Clinical Safety and Toxicity Package ▪ Cardiovascular, Respiratory and CNS Safety Pharmacology Study (Single Escalating Dose @ 1, 10 and 100 mg/kg in Cyno monkey): No significant findings ▪ 28 - Day Toxicity Study with a 4 week recovery period (Repeat Weekly Dosing @ 10, 50 a

  13. Slide 13: Human Clinical Trials Confirm Excellent Lenzilumab Safety and Tolerability Profile

    Human Clinical Trials Confirm Excellent Lenzilumab Safety and Tolerability Profile (> 100 Patients *) Study ♦ Population Objectives Enrollment /Dose Safety Results Phase I Single - dose, dose - escalation Healthy adult volunteers • Safety/tolerability • PK • Immunogenicity (n=12) • 3 / 1 mg/kg • 3 /

  14. Slide 14: Lenzilumab Development Plan Has Top KOL Support

    Lenzilumab CAR - T Development Plan Has Top KOL Support • Significant on - going interactions with top KOLs; proactive study ideas • Leading centers interested and actively engaged: • Massachusetts General Hospital • Moffitt • Olivia Newton - John Cancer Research Institute • Memorial Sloan Kettering

  15. Slide 15: Pivotal/Registration Studies with Marketed CAR-Ts in Labeled Indications

    Pivotal/Registration Studies with Marketed CAR - Ts in Labeled Indications o Parallel/Staggered Approach 1. Investigator - initiated studies 1H 2019 in cooperation with CAR - T players 2 . Humanigen Pre - IND meeting o Discuss potential for registration on existing studies and/or “ next - step” adap

  16. Slide 16: Pipeline

    Pipeline Preclinical Phase I Phase II Phase III BLA Lenzilumab (anti - GM - CSF mAb ) Prophylaxis CAR - T - induced serious A/ Es , potential improved efficacy (CAR - T companion/booster) CMML (monotherapy in salvage patients - fully enrolled) Ifabotuzumab (anti - EphA3 mAb ) GBM (monotherapy in sal

  17. Slide 17: Ifabotuzumab: First-in-Class, EphA3 Monoclonal Antibody

    Ifabotuzumab : First - in - Class, EphA3 Monoclonal Antibody Ifabotuzumab o Targets EphA3 receptor Phase I bio - imaging study in GBM CAR being designed using ifabotuzumab Already developed an ADC (BD discussions) Potential bispecific (BD discussions) Potential radio - pharmaceutical (BD discussions

  18. Slide 18: HGEN005, Anti-EMR1: First-in-Class, Monoclonal Antibody

    HGEN005 , Anti - EMR1: First - in - Class, Monoclonal Antibody HGEN005 Human (EGF) epidermal growth factor - like module containing mucin - like hormone receptor 1 (EMR1 ) - surface receptor EGF - seven - transmembrane (EGF - TM7) family of G - protein coupled receptors Surface expression of EMR1 re

  19. Slide 19: Summary

    Summary Lenzilumab has the potential to make CAR - T safer, more effective and a more routine out - patient procedure Clinical/regulatory plan developed for optimal value and delivery of key data near term Additional potential pipeline value: Lenzilumab in CMML fully recruited Ifabotuzumab in gliobl

Humanigen — Investor Presentation (August 2018) on 6ix